REPORT ID 13354

United States Blood-Brain Barrier Transport Drugs Market Report 2017

Publish Date
21-Nov-17
Pages
109
Format
Electronic (PDF)

In this report, the United States Blood-Brain Barrier Transport Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Blood-Brain Barrier Transport Drugs in these regions, from 2012 to 2022 (forecast).

United States Blood-Brain Barrier Transport Drugs market competition by top manufacturers/players, with Blood-Brain Barrier Transport Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Cyclenium
    BioAdvance
    EIP Pharma
    Bioasis
    Immune Pharmaceuticals
    AZ Therapies
    Palobiofarma
    Bach Pharma
    BrainsGate
    CarThera
    Dainippon Sumitomo Pharma
    Fluorinov Pharma
    Fondazione Telethon
    Minoryx
    NewGen Therapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Carrier-mediated Transport
    Receptor-mediated Transport
    Absorptive-mediated Transport
    Active Efflux Transport
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Alzheimer's Disease
    Epilepsy
    Parkinson's Disease
    Multiple Sclerosis
    Hunter's Syndrome
    Brain Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Blood-Brain Barrier Transport Drugs Market Report 2017
1 Blood-Brain Barrier Transport Drugs Overview
    1.1 Product Overview and Scope of Blood-Brain Barrier Transport Drugs
    1.2 Classification of Blood-Brain Barrier Transport Drugs by Product Category
        1.2.1 United States Blood-Brain Barrier Transport Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Blood-Brain Barrier Transport Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Carrier-mediated Transport
        1.2.4 Receptor-mediated Transport
        1.2.5 Absorptive-mediated Transport
        1.2.6 Active Efflux Transport
        1.2.7 Others
    1.3 United States Blood-Brain Barrier Transport Drugs Market by Application/End Users
        1.3.1 United States Blood-Brain Barrier Transport Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Alzheimer's Disease
        1.3.3 Epilepsy
        1.3.4 Parkinson's Disease
        1.3.5 Multiple Sclerosis
        1.3.6 Hunter's Syndrome
        1.3.7 Brain Cancer
        1.3.8 Others
    1.4 United States Blood-Brain Barrier Transport Drugs Market by Region
        1.4.1 United States Blood-Brain Barrier Transport Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
        1.4.5 New England Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
        1.4.6 The South Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Blood-Brain Barrier Transport Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Blood-Brain Barrier Transport Drugs (2012-2022)
        1.5.1 United States Blood-Brain Barrier Transport Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Blood-Brain Barrier Transport Drugs Revenue and Growth Rate (2012-2022)

2 United States Blood-Brain Barrier Transport Drugs Market Competition by Players/Suppliers
    2.1 United States Blood-Brain Barrier Transport Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Blood-Brain Barrier Transport Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Blood-Brain Barrier Transport Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Blood-Brain Barrier Transport Drugs Market Competitive Situation and Trends
        2.4.1 United States Blood-Brain Barrier Transport Drugs Market Concentration Rate
        2.4.2 United States Blood-Brain Barrier Transport Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Blood-Brain Barrier Transport Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Blood-Brain Barrier Transport Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Blood-Brain Barrier Transport Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Blood-Brain Barrier Transport Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Blood-Brain Barrier Transport Drugs Price by Region (2012-2017)

4 United States Blood-Brain Barrier Transport Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Blood-Brain Barrier Transport Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Blood-Brain Barrier Transport Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Blood-Brain Barrier Transport Drugs Price by Type (2012-2017)
    4.4 United States Blood-Brain Barrier Transport Drugs Sales Growth Rate by Type (2012-2017)

5 United States Blood-Brain Barrier Transport Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Blood-Brain Barrier Transport Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Blood-Brain Barrier Transport Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Blood-Brain Barrier Transport Drugs Players/Suppliers Profiles and Sales Data
    6.1 Cyclenium
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Cyclenium Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 BioAdvance
        6.2.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 BioAdvance Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 EIP Pharma
        6.3.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 EIP Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Bioasis
        6.4.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Bioasis Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Immune Pharmaceuticals
        6.5.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Immune Pharmaceuticals Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 AZ Therapies
        6.6.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 AZ Therapies Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Palobiofarma
        6.7.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Palobiofarma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Bach Pharma
        6.8.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Bach Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 BrainsGate
        6.9.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 BrainsGate Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 CarThera
        6.10.2 Blood-Brain Barrier Transport Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 CarThera Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Dainippon Sumitomo Pharma
    6.12 Fluorinov Pharma
    6.13 Fondazione Telethon
    6.14 Minoryx
    6.15 NewGen Therapeutics

7 Blood-Brain Barrier Transport Drugs Manufacturing Cost Analysis
    7.1 Blood-Brain Barrier Transport Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Blood-Brain Barrier Transport Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Blood-Brain Barrier Transport Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Blood-Brain Barrier Transport Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Blood-Brain Barrier Transport Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Blood-Brain Barrier Transport Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Blood-Brain Barrier Transport Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Blood-Brain Barrier Transport Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Blood-Brain Barrier Transport Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer